PPARγ Agonist Pioglitazone Reverses Memory Impairment and Biochemical Changes in a Mouse Model of Type 2 Diabetes Mellitus

CNS Neuroscience and Therapeutics

Volumn 18, Issue 8, 2012, Pages 659-666

  Jiang, Li Ying ^a   Tang, Su Su ^a   Wang, Xiao Yun ^a   Liu, Li Ping ^b   Long, Yan ^a   Hu, Mei ^a   Liao, Ming Xing ^a   Ding, Qi Long ^a   Hu, Wei ^b   Li, Jia Chang ^a   Hong, Hao ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

amyloid peptide; BACE1; Cognition; Diabetes mellitus; NF B; Pioglitazone

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BETA SECRETASE 1; BRAIN PROTEIN; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; PIOGLITAZONE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPOINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; LEARNING TEST; LIPID DIET; MALE; MAZE TEST; MEMORY; MEMORY DISORDER; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; STREPTOZOCIN DIABETES; TRIACYLGLYCEROL BLOOD LEVEL;

AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; BEHAVIOR, ANIMAL; BLOOD GLUCOSE; BLOTTING, WESTERN; BRAIN CHEMISTRY; COGNITION DISORDERS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLYCOSYLATION END PRODUCTS, ADVANCED; HYPOGLYCEMIC AGENTS; IMMUNOHISTOCHEMISTRY; INSULIN; MALE; MAZE LEARNING; MEMORY DISORDERS; MICE; MICE, INBRED ICR; NF-KAPPA B; PPAR GAMMA; THIAZOLIDINEDIONES; TRIGLYCERIDES;

EID: 84864753094     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2012.00341.x     Document Type: Article

References (39)

1. S Roriz-Filho J, Sá-Roriz TM, Rosset I, et al. (Pre)diabetes, brain aging, and cognition. Biochim Biophys Acta 2009;1792:432-443.
2. Kodl CT, Seaquist ER. Cognitive dysfunction and diabetes mellitus. Endocr Rev 2008;29:494-511.
3. Miles WR, Root HF. Psychologic tests applied in diabetic patients. Arch Intern Med 1922;30:767-777.
4. Mijnhout GS, Scheltens P, Diamant M, et al. Diabetic encephalopathy: A concept in need of a definition. Diabetologia 2006;49:1447-1448.
5. Janson J, Laedtke T, Parisi JE, O'Brien P, Petersen RC, Butler PC. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 2004;53:474-481.
6. Han W, Li C. Linking type 2 diabetes and Alzheimer's disease. Proc Natl Acad Sci U S A 2010;107:6557-6558.
7. Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 2002;51:1256-1262.
8. Yoneda S, Hara H, Hirata A, Fukushima M, Inomata Y, Tanihara H. Vitreous fluid levels of beta-amyloid (1-42) and tau in patients with retinal diseases. Jpn J Ophthalmol 2005;49:106-108.
9. Valente T, Gella A, Fernàndez-Busquets X, Unzeta M, Durany N. Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer's disease and diabetes mellitus. Neurobiol Dis 2010;37:67-76.
10. Li ZG, Zhang W, Sima AA. Alzheimer-like changes in rat models of spontaneous diabetes. Diabetes 2007;56:1817-1824.
11. Liu Y, Liu H, Yang J, et al. Increased amyloid beta-peptide (1-40) level in brain of streptozotocin-induced diabetic rats. Neuroscience 2008;153:796-802.
12. Hong H, Liu LP, Liao JM, et al. Downregulation of LRP1 at the blood-brain barrier in streptozotocin-induced diabetic mice. Neuropharmacology 2009;56:1054-1059.
13. Kamal A, Biessels GJ, Duis SE, Gispen WH. Learning and hippocampal synaptic plasticity in streptozotocin-diabetic rats: interaction of diabetes and ageing. Diabetologia 2000;43:500-506.
14. Sima AA, Li ZG. The effect of C-peptide on cognitive dysfunction and hippocampal apoptosis in type 1 diabetic rats. Diabetes 2005;54:1497-1505.
15. Jolivalt CG, Hurford R, Lee CA, Dumaop W, Rockenstein E, Masliah E. Type 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic mice. Exp Neurol 2010;223:422-431.
16. Wang X, Zheng W, Xie JW, et al. Insulin deficiency exacerbates cerebral amyloidosis and behavioral deficits in an Alzheimer transgenic mouse model. Mol Neurodegener 2010;5:46-58.
17. Ho L, Qin W, Pompl PN, et al. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J 2004;18:902-904.
18. Takeda S, Sato N, Uchio-Yamada K, et al. Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci U S A 2010;107:7036-7041.
19. Sood V, Colleran K, Burge MR. Thiazolidinediones: A comparative review of approved uses. Diabetes Technol Ther 2000;2:429-440.
20. Nicolakakis N, Hamel E. The Nuclear receptor PPARgamma as a therapeutic target for cerebrovascular and brain dysfunction in Alzheimer's disease. Front Aging Neurosci 2010;2:21-30.
21. Luo J, Quan J, Tsai J, et al. Nongenetic mouse models of non-insulin-dependent diabetes mellitus. Metabolism 1998;47:663-668.
22. Kimura R, Devi L, Ohno M. Partial reduction of BACE1 improves synaptic plasticity, recent and remote memories in Alzheimer's disease transgenic mice. J Neurochem 2011;113:248-261.
23. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 1984;11:47-60.
24. Joanna M. Exclusively targeting β-secretase to lipid rafts by GPI-anchor addition up-regulates β-site processing of the amyloid precursor protein. Proc Natl Acad Sci U S A 2003;100:11735-11740.
25. Messier C, Gagnon M. Glucose regulation and cognitive functions: Relation to Alzheimer's disease and diabetes. Behav Brain Res 1996;75:1-11.
26. Brands AM, Kessels RP, de Haan EH, Kappelle LJ, Biessels GJ. Cerebral dysfunction in type 1 diabetes: Effects of insulin, vascular risk factors and blood glucose levels. Eur J Pharmacol 2004;490:159-168.
27. Lobnig BM, Kromeke O, Optenhostert-Porst C, Wolf OT. Hippocampal volume and cognitive performance in long-standing Type 1 diabetic patients without macrovascular complications. Diabet Med. 2005;23:32-39.
28. Mackic JB, Bading J, Ghiso J, Walker L, Wisniewski T, Frangione B, Zlokovic BV. 2002. Circulating amyloid-β peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer's disease lesions. Vasc Pharmacol 38:303-313.
29. Guglielmotto M, Aragno M, Tamagno E, et al. AGEs/RAGE complex upregulates BACE1 via NF-kappaB pathway activation. Neurobiol Aging 2012;33:196.e13-27.
30. Liu LP, Hong, H, Liao JM, et al. Up-regulation of RAGE at the blood-brain barrier in streptozotocin-induced diabetic mice. Synapse 2009;63:636-642.
31. Bourne KZ, Ferrari DC, Lange-Dohna C, Rossner S, Wood TG, Perez-Polo JR. Differential regulation of BACE1 promoter activity by nuclear factor-B in neurons and glia upon exposure to beta-amyloid peptides. J Neurosci Res 2007;85:1194-1204.
32. Bucala R, Cerami A. Advanced glycosylation: Chemistry, biology, and implications for diabetes and aging. Adv Pharmacol 1992;23:1-34.
33. Thorpe SR, Baynes JW. Maillard reaction products in tissue proteins: New products and new perspectives. Amino Acids 2003;25:275-281.
34. Yamagishi S, Matsui T, Nakamura K. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes. Curr Drug Targets 2007;8:1138-1143.
35. Derosa G. Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: Comparison with other oral antihyperglycaemic agents. Drugs 2010;70:1945-1961.
36. Mandrekar-Colucci S, Landreth GE. Nuclear receptors as therapeutic targets for Alzheimer's disease. Expert Opin Ther Targets. 2011;15:1085-1097.
37. Yamagishi S, Nakamura K, Matsui T. Regulation of advanced glycation end product (AGE)-receptor (RAGE) system by PPAR-gamma agonists and its implication in cardiovascular disease. Pharmacol Res 2009;60:174-178.
38. Marx N, Walcher D, Ivanova N, et al. Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products. Diabetes 2004;53:2662-2668.
39. Maeshiba Y, Kiyota Y, Yamashita K, Yoshimura Y, Motohashi M, Tanayama S. Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys. Arzneimittelforschung 1997;47:29-35.